Zeiss Group is looking to increase investments in China, the German optical systems and optoelectronics manufacturer said, spurred by growth opportunities stemming from an aging population with vision problems.
IACTA Pharmaceuticals Announces Expansion of Scientific Advisory Board with Two World-Renowned Key Opinion Leaders streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced on Nov. 19 that the first set of patients.
/PRNewswire/ Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced on Nov. 19 that the first set of patients.
Published: Dec 25, 2020
SHANGHAI, Dec. 25, 2020 /PRNewswire/
Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, announced on December 24th the clearance of the Investigational New Drug (IND) for Phase III trial of ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension) for the treatment of Uveitic Macular Edema (UME) by China National Medical Products Administration (NMPA). It will be the first clinical trial in China for UME treatment, and also the first one in China to adopt suprachoroidal space (SCS) injection, which is expected to provide a new treatment option for Chinese patients with UME.
This is also the first IND approval for Arctic Vision. As an emerging Ophthalmology company, we are very excited. It is a major milestone, said Eddy (Hoi Ti) Wu, Ph.D., Founder and CEO of Arctic Vision. It took only 9 months for us to get the IND approval after obtaining the exclusive license of